Skip to main content
SpringerLink
Log in

Tactics and technologies to manage nonadherence in patients with schizophrenia

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

The occurrence of treatment nonadherence among patients with schizophrenia is clinically significant. However, studies show that clinicians do not make systematic efforts to identify and monitor it over time. This paper reviews the various tactics for identifying and monitoring adherence behavior. A comprehensive review of published studies comparing typical and atypical antipsychotics in terms of medication adherence yields mixed results at best. Changing forces in the delivery of health care in the United States will promote efforts to improve the recognition of nonadherence in patients with schizophrenia and develop strategies and tactics to decrease the current rates of nonadherence. Such tactics are described in this paper, and emerging best practices are identified. Ultimately, if nonadherence rates are to decrease, it will be necessary to align the incentives of the treater and the treated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Herz MI, Glazer W, Mirza M, et al.: Treating prodromal episodes to prevent relapse in schizophrenia. Br J Psychiatry 1989, 155(Suppl 5):123–127.

    Google Scholar 

  2. Spaniel F, Vohlidka P, Hrdlicka J, et al.: ITAREPS: Information Technology Aided Relapse Prevention Programme in Schizophrenia. Schizophr Res 2008, 98:312–317.

    Article  PubMed  Google Scholar 

  3. Byerly MJ, Thompson A, Carmody T, et al.: Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 2007, 58:844–847.

    Article  PubMed  Google Scholar 

  4. Lacro JP, Dunn LB, Dolder CR, et al.: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892–909.

    PubMed  Google Scholar 

  5. Cooper D, Moisan J, Gregoire JP: Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007, 68:818–825.

    PubMed  CAS  Google Scholar 

  6. Law MR, Soumerai SB, Ross-Degnan DR, Adams AS: A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008, 69:47–53.

    PubMed  Google Scholar 

  7. Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886–891.

    Article  PubMed  Google Scholar 

  8. Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995, 21:419–429.

    PubMed  CAS  Google Scholar 

  9. Gilmer TP, Dolder CR, Lacro JP, et al.: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692–699.

    Article  PubMed  Google Scholar 

  10. Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23:2305–2312.

    Article  PubMed  Google Scholar 

  11. Kane JM: Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006, 67(Suppl 5):9–14.

    PubMed  CAS  Google Scholar 

  12. Velligan DI, Wang M, Diamond P, et al.: Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007, 58:1187–1192.

    Article  PubMed  Google Scholar 

  13. Ascher-Svanum H, Zhu B, Faries D, et al.: A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006, 67:1114–1123.

    PubMed  Google Scholar 

  14. Velligan DI, Lam YW, Glahn DC, et al.: Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006, 32:724–742.

    Article  PubMed  Google Scholar 

  15. Byerly M, Fisher R, Whatley K, et al.: A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005, 133:129–133.

    Article  PubMed  Google Scholar 

  16. McClellan TA, Cowan G: Use of antipsychotic and antidepressant drugs by chronically ill patients. Am J Psychiatry 1970, 126:1771–1773.

    PubMed  CAS  Google Scholar 

  17. Valenstein M, Barry KL, Blow FC, et al.: Agreement between seriously mentally ill veterans and their clinicians about medication compliance. Psychiatr Serv 1998, 49:1043–1048.

    PubMed  CAS  Google Scholar 

  18. Woltmann EM, Valenstein M, Welsh DE, et al.: Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. Psychiatr Serv 2007, 58:864–867.

    Article  PubMed  Google Scholar 

  19. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007, 298:61–69.

    Article  PubMed  CAS  Google Scholar 

  20. Pomykacz B, Mao M, Weiss RD, Teter CJ: A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder. Harv Rev Psychiatry 2007, 15:259–263.

    Article  PubMed  Google Scholar 

  21. Byerly MJ, Nakonezny PA, Rush AJ: The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res 2008, 100:60–69.

    Article  PubMed  Google Scholar 

  22. Diaz E, Levine HB, Sullivan MC, et al.: Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001, 26:325–329.

    PubMed  CAS  Google Scholar 

  23. Nakonezny PA, Byerly MJ, Rush AJ: Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. Psychiatry Res 2008, 157:259–263.

    Article  PubMed  Google Scholar 

  24. Remington G, Kwon J, Collins A, et al.: The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007, 90:229–237.

    Article  PubMed  Google Scholar 

  25. Steiner JF, Koepsell TD, Fihn SD, Inui TS: A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988, 26:814–823.

    Article  PubMed  CAS  Google Scholar 

  26. Dolder CR, Lacro JP, Dunn LB, Jeste DV: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002, 159:103–108.

    Article  PubMed  Google Scholar 

  27. Valenstein M, Copeland LA, Blow FC, et al.: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40:630–639.

    Article  PubMed  Google Scholar 

  28. Eaddy M, Grogg A, Locklear J: Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005, 27:263–272.

    Article  PubMed  Google Scholar 

  29. Frazier RS, Casper ES: A comparative study of clinical events as triggers for psychiatric readmission of multiple recidivists. Psychiatr Serv 1998, 49:1423–1425.

    PubMed  CAS  Google Scholar 

  30. Marder SR: Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998, 59(Suppl 3):21–25.

    PubMed  Google Scholar 

  31. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209–1223.

    Article  PubMed  CAS  Google Scholar 

  32. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414–425.

    Article  PubMed  Google Scholar 

  33. Rosenheck R, Chang S, Choe Y, et al.: Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000, 61:382–386.

    PubMed  CAS  Google Scholar 

  34. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH: Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 2006, 144:177–189.

    Article  PubMed  Google Scholar 

  35. Al-Zakwani IS, Barron JJ, Bullano MF, et al.: Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003, 19:619–626.

    Article  PubMed  Google Scholar 

  36. Becker MA, Young MS, Ochshorn E, Diamond RJ: The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Policy Ment Health 2007, 34:307–314.

    Article  PubMed  Google Scholar 

  37. Vanelli M, Burstein P, Cramer J: Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv 2001, 52:1248–1250.

    Article  PubMed  CAS  Google Scholar 

  38. Grunebaum MF, Weiden PJ, Olfson M: Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry 2001, 62:394–399.

    PubMed  CAS  Google Scholar 

  39. Olfson M, Mechanic D, Hansell S, et al.: Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000, 51:216–222.

    Article  PubMed  CAS  Google Scholar 

  40. Cabeza IG, Amador MS, Lopez CA, Gonzalez de Chavez M: Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000, 41:349–355.

    Article  PubMed  CAS  Google Scholar 

  41. Menzin J, Boulanger L, Friedman M, et al.: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003, 54:719–723.

    Article  PubMed  Google Scholar 

  42. Diaz E, Neuse E, Sullivan MC, et al.: Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004, 65:354–360.

    Article  PubMed  Google Scholar 

  43. Nakonezny PA, Byerly MJ: Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first-vs. second-generation antipsychotics. Schizophr Res 2006, 82:107–114.

    Article  PubMed  Google Scholar 

  44. Perkins DO, Johnson JL, Hamer RM, et al.: Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006, 83:53–63.

    Article  PubMed  Google Scholar 

  45. Hogarty GE, Schooler NR, Ulrich R, et al.: Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979, 36:1283–1294.

    PubMed  CAS  Google Scholar 

  46. Buchanan A: A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992, 22:787–797.

    Article  PubMed  CAS  Google Scholar 

  47. Weiden P, Rapkin B, Zygmunt A, et al.: Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995, 46:1049–1054.

    PubMed  CAS  Google Scholar 

  48. Nageotte C, Sullivan G, Duan N, Camp PL: Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol 1997, 32:49–56.

    Article  PubMed  CAS  Google Scholar 

  49. Garavan J, Browne S, Gervin M, et al.: Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998, 39:215–219.

    Article  PubMed  CAS  Google Scholar 

  50. Keith SJ, Kane JM: Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003, 64:1308–1315.

    Article  PubMed  Google Scholar 

  51. Chue P, Emsley R: Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007, 21:441–448.

    Article  PubMed  CAS  Google Scholar 

  52. Schatzberg AF, Cole JO, Debattista C: Manual of Clinical Psychopharmacology, edn 6. Washington, DC: American Psychiatric Publishing; 2007.

    Google Scholar 

  53. Glazer WM, Kane JM: Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992, 53:426–433.

    PubMed  CAS  Google Scholar 

  54. Glazer WM: Who receives long-acting antipsychotic medications? Psychiatr Serv 2007, 58:437.

    Article  PubMed  Google Scholar 

  55. Glazer WM: The depot paradox. Behav Healthc 2007, 27:44–46.

    PubMed  Google Scholar 

  56. Eisenthal S, Emery R, Lazare A, Udin H: “Adherence” and the negotiated approach to patienthood. Arch Gen Psychiatry 1979, 36:393–398.

    PubMed  CAS  Google Scholar 

  57. National Council on Patient Information and Education: Children and America’s Other Drug Problem: Guidelines for Improving Prescription Medicine Use Among Children and Teenagers. Bethesda, MD: National Council on Patient Information and Education; 1989.

    Google Scholar 

  58. National Institute of Mental Health: Research on Adherence to Interventions for Mental Disorders. Bethesda, MD: National Institute of Mental Health; 1999. [NIMH publication no. PA-00-016.]

    Google Scholar 

  59. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353:487–497.

    Article  PubMed  CAS  Google Scholar 

  60. Moore TA, Covell NH, Essock SM, Miller AL: Real-world antipsychotic treatment practices. Psychiatr Clin North Am 2007, 30:401–416.

    Article  PubMed  Google Scholar 

  61. Weiden PJ, Rao N: Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculum. Acad Psychiatry 2005, 29:203–210.

    Article  PubMed  Google Scholar 

  62. Byerly MJ, Nakonezny PA, Lescouflair E: Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007, 30:437–452.

    Article  PubMed  Google Scholar 

  63. Corrigan PW, Liberman RP, Engel JD: From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990, 41:1203–1211.

    PubMed  CAS  Google Scholar 

  64. Perkins DO: Adherence to antipsychotic medications. J Clin Psychiatry 1999, 60(Suppl 21):25–30.

    PubMed  Google Scholar 

  65. Heinssen RK: Improving medication compliance of a patient with schizophrenia through collaborative behavioral therapy. Psychiatr Serv 2002, 53:255–257.

    Article  PubMed  Google Scholar 

  66. Noordsy DL, Torrey WC, Mead S, et al.: Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment. J Clin Psychiatry 2000, 61(Suppl 3):22–29.

    PubMed  Google Scholar 

  67. Engel GL: The clinical application of the biopsychosocial model. Am J Psychiatry 1980, 137:535–544.

    PubMed  CAS  Google Scholar 

  68. Zygmunt A, Olfson M, Boyer CA, Mechanic D: Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002, 159:1653–1664.

    Article  PubMed  Google Scholar 

  69. Dolder CR, Lacro JP, Leckband S, Jeste DV: Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003, 23:389–399.

    Article  PubMed  Google Scholar 

  70. Gray R, Wykes T, Gournay K: From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J Psychiatr Ment Health Nurs 2002, 9:277–284.

    Article  PubMed  CAS  Google Scholar 

  71. Lincoln TM, Wilhelm K, Nestoriuc Y: Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007, 96:232–245.

    Article  PubMed  CAS  Google Scholar 

  72. Nose M, Barbui C, Gray R, Tansella M: Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003, 183: 197–206.

    Article  PubMed  Google Scholar 

  73. Regier DA, Farmer ME, Rae DS, et al.: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511–2518.

    Article  PubMed  CAS  Google Scholar 

  74. Hunt GE, Bergen J, Bashir M: Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002, 54:253–264.

    Article  PubMed  Google Scholar 

  75. Bellack AS, DiClemente CC: Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999, 50:75–80.

    PubMed  CAS  Google Scholar 

  76. Wilk J, Marcus SC, West J, et al.: Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis 2006, 194:454–457.

    Article  PubMed  Google Scholar 

  77. Ho AP, Tsuang JW, Liberman RP, et al.: Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. Am J Psychiatry 1999, 156:1765–1770.

    PubMed  CAS  Google Scholar 

  78. Barrowclough C, Haddock G, Tarrier N, et al.: Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001, 158:1706–1713.

    Article  PubMed  CAS  Google Scholar 

  79. Haddock G, Barrowclough C, Tarrier N, et al.: Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry 2003, 183:418–426.

    Article  PubMed  Google Scholar 

  80. Bellack AS, Bennett ME, Gearon JS, et al.: A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006, 63:426–432.

    Article  PubMed  Google Scholar 

  81. Kemp R, Hayward P, Applewhaite G, et al.: Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996, 312:345–349.

    PubMed  CAS  Google Scholar 

  82. Kemp R, Kirov G, Everitt B, et al.: Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998, 172:413–419.

    Article  PubMed  CAS  Google Scholar 

  83. O’Donnell C, Donohoe G, Sharkey L, et al.: Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003, 327:834.

    Article  PubMed  Google Scholar 

  84. McIntosh AM, Conlon L, Lawrie SM, Stanfield AC: Compliance therapy for schizophrenia. Cochrane Database Syst Rev 2006, 3:CD003442.

  85. Gray R, Leese M, Bindman J, et al.: Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry 2006, 189:508–514.

    Article  PubMed  Google Scholar 

  86. Byerly MJ, Fisher R, Carmody T, Rush AJ: A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005, 66:997–1001.

    PubMed  CAS  Google Scholar 

  87. Velligan DI, Mueller J, Wang M, et al.: Use of environmental supports among patients with schizophrenia. Psychiatr Serv 2006, 57:219–224.

    Article  PubMed  Google Scholar 

  88. Velligan DI, Diamond PM, Mintz J, et al.: The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 2008, 34:483–493.

    Article  PubMed  Google Scholar 

  89. Pitschel-Walz G, Bauml J, Bender W, et al.: Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry 2006, 67:443–452.

    Article  PubMed  Google Scholar 

  90. Claassen D: Financial incentives for antipsychotic depot medication: ethical issues. J Med Ethics 2007, 33:189–193.

    Article  PubMed  Google Scholar 

  91. Glazer WM: What are “best practices”? Understanding the concept. Hosp Community Psychiatry 1994, 45:1067–1068.

    PubMed  CAS  Google Scholar 

  92. Heyscue BE, Levin GM, Merrick JP: Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998, 49:1232–1234.

    PubMed  CAS  Google Scholar 

  93. Velligan DI, Bow-Thomas CC, Huntzinger C, et al.: Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 2000, 157:1317–1323.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Glazer Medical Solutions, 8 Nassau Lane, Key West, FL, 33040, USA

    William M. Glazer

Authors
  1. William M. Glazer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathew J. Byerly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William M. Glazer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glazer, W.M., Byerly, M.J. Tactics and technologies to manage nonadherence in patients with schizophrenia. Curr Psychiatry Rep 10, 359–369 (2008). https://doi.org/10.1007/s11920-008-0057-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-008-0057-7

Keywords

Search

Navigation